Literature DB >> 24082309

Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.

Sophie Bayard1, Muriel Croisier Langenier, Yves Dauvilliers.   

Abstract

STUDY
OBJECTIVES: To assess whether the frequency of impulse control disorders (ICDs), addictive behaviors, impulsivity, and impairment of decision-making task performance under ambiguous and risky conditions were present in patients with restless legs syndrome (RLS) and whether changes could be related to dopaminergic medications.
DESIGN: Case-control prospective study.
SETTING: Academic Sleep Disorders Center. PARTICIPANTS: Of the 149 participants, there were 39 who were drug free with primary RLS, 50 who were taking dopamine agonists (DA), and 60 control subjects. Participants were assessed with a clinical interview screening for ICDs, augmentation syndrome, impulsivity, depression, and addictive behaviors. All participants completed two decision-making tasks, one under an ambiguous condition (Iowa Gambling Task) and the other under a risky condition (Game of Dice Task). Drug-free patients with RLS underwent 1 night of polysomnography recording. MEASUREMENTS AND
RESULTS: Seventy percent of patients were treated with pramipexole (median dose, 0.36 mg), and 30% with ropinirole (median dose, 0.75 mg). Median duration of DA intake was 11 mo (range, 1-72 mo). No differences were found on impulsivity scores, ICDs, and substance addiction between drug-free patients or those taking DA, or control subjects. Patients with RLS reported more depressive symptoms than control subjects, but without differences between patients taking or not taking DA. Drug-free and treated patients demonstrated reduced performances on the Iowa Gambling Task but not on the Game of Dice Task compared to control subjects, with no differences between patients taking medications and those who were not. No association was found between decision-making task performances, or polysomnographic and clinical variables.
CONCLUSION: Impulse control disorders, impulsivity, and substance addiction were infrequent in drug-free patients with restless legs syndrome or those treated with a low dose of dopamine agonists. However, patients with restless legs syndrome, either drug free or taking dopamine agonists, had preferences toward risky choices on the Iowa Gambling Task, which led to negative consequences in the long run, a condition potentially leading to further development of impulse control disorders.

Entities:  

Keywords:  Game of Dice Task; Iowa Gambling Task; Restless legs syndrome; decision-making; dopamine agonist; impulsive compulsive disorders

Mesh:

Substances:

Year:  2013        PMID: 24082309      PMCID: PMC3773199          DOI: 10.5665/sleep.3044

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  29 in total

Review 1.  Emotion, decision making and the orbitofrontal cortex.

Authors:  A Bechara; H Damasio; A R Damasio
Journal:  Cereb Cortex       Date:  2000-03       Impact factor: 5.357

2.  Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale.

Authors:  Daniel Weintraub; Eugenia Mamikonyan; Kimberly Papay; Judith A Shea; Sharon X Xie; Andrew Siderowf
Journal:  Mov Disord       Date:  2011-12-01       Impact factor: 10.338

3.  Decision-making impairments in patients with pathological gambling.

Authors:  Matthias Brand; Elke Kalbe; Kirsten Labudda; Esther Fujiwara; Josef Kessler; Hans J Markowitsch
Journal:  Psychiatry Res       Date:  2005-01-30       Impact factor: 3.222

4.  Neuropsychological features of patients with Parkinson's disease and impulse control disorders.

Authors:  Anna Rita Bentivoglio; Eleonora Baldonero; Lucia Ricciardi; Francesca De Nigris; Antonio Daniele
Journal:  Neurol Sci       Date:  2012-11-18       Impact factor: 3.307

Review 5.  Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments.

Authors:  Leonardo F Fontenelle; Sanne Oostermeijer; Ben J Harrison; Christos Pantelis; Murat Yücel
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

6.  Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome.

Authors:  M Manconi; R Ferri; M Zucconi; S Clemens; L Giarolli; V Bottasini; L Ferini-Strambi
Journal:  Neurology       Date:  2011-06-29       Impact factor: 9.910

7.  Frontal lobe dysfunction in pathological gambling patients.

Authors:  Paolo Cavedini; Giovanna Riboldi; Roberto Keller; Arcangela D'Annucci; Laura Bellodi
Journal:  Biol Psychiatry       Date:  2002-02-15       Impact factor: 13.382

Review 8.  Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.

Authors:  Richard P Allen; Daniel Picchietti; Wayne A Hening; Claudia Trenkwalder; Arthur S Walters; Jacques Montplaisi
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

9.  Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome.

Authors:  Arthur S Walters; Cheryl LeBrocq; Anjana Dhar; Wayne Hening; Ray Rosen; Richard P Allen; Claudia Trenkwalder
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

10.  Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task.

Authors:  K I Bolla; D A Eldreth; E D London; K A Kiehl; M Mouratidis; C Contoreggi; J A Matochik; V Kurian; J L Cadet; A S Kimes; F R Funderburk; M Ernst
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

View more
  18 in total

Review 1.  Decision Making Under Objective Risk Conditions-a Review of Cognitive and Emotional Correlates, Strategies, Feedback Processing, and External Influences.

Authors:  Johannes Schiebener; Matthias Brand
Journal:  Neuropsychol Rev       Date:  2015-04-18       Impact factor: 7.444

Review 2.  An update in sleep neurology: the latest bedtime stories.

Authors:  K N Anderson
Journal:  J Neurol       Date:  2014-12-10       Impact factor: 4.849

3.  New Onset of Compulsive Gambling Associated With Modafinil: A Case Report.

Authors:  Wales T George; Ranji Varghese; Imran S Khawaja
Journal:  Prim Care Companion CNS Disord       Date:  2015-01-01

4.  Quality measures for the care of adult patients with restless legs syndrome.

Authors:  Lynn Marie Trotti; Cathy A Goldstein; Christopher G Harrod; Brian B Koo; Denise Sharon; Rochelle Zak; Ronald D Chervin
Journal:  J Clin Sleep Med       Date:  2015-03-15       Impact factor: 4.062

Review 5.  Sleep in Parkinson's Disease with Impulse Control Disorder.

Authors:  Michela Figorilli; Patrizia Congiu; Rosa Lecca; Gioia Gioi; Roberto Frau; Monica Puligheddu
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-11       Impact factor: 5.081

6.  Motor and non-motor symptoms in functional parkinsonism responsive to transcranial magnetic stimulation: a case report.

Authors:  Cecilia Bonnet; Francine Mesrati; Emmanuel Roze; Cécile Hubsch; Bertrand Degos
Journal:  J Neurol       Date:  2016-02-25       Impact factor: 4.849

7.  Deciphering Age Differences in Experience-Based Decision-Making: The Role of Sleep.

Authors:  Xue-Rui Peng; Yun-Rui Liu; Dong-Qiong Fan; Xu Lei; Quan-Ying Liu; Jing Yu
Journal:  Nat Sci Sleep       Date:  2020-09-29

8.  Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.

Authors:  Emir Celik; Hande Mefkure Ozkaya; Burc Cagri Poyraz; Tarik Saglam; Pinar Kadioglu
Journal:  Endocrine       Date:  2018-09-11       Impact factor: 3.633

Review 9.  The neurobiological basis of narcolepsy.

Authors:  Carrie E Mahoney; Andrew Cogswell; Igor J Koralnik; Thomas E Scammell
Journal:  Nat Rev Neurosci       Date:  2019-02       Impact factor: 34.870

10.  Decision-Making in Patients with Hyperthyroidism: A Neuropsychological Study.

Authors:  Lili Yuan; Yanghua Tian; Fangfang Zhang; Huijuan Ma; Xingui Chen; Fang Dai; Kai Wang
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.